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The term microbiota is used to describe the complete population
of microorganisms that populate a certain location, such as the
gut, and is preferred to the term flora as the former incorporates
not just bacteria but also archaea, viruses, and other microorgan-
isms, such as protozoa. Though the potential role of the microbi-
ota (through such concepts as ‘‘the putrefactive principle
associated with faeces’’ and ‘‘intestinal toxins’’) in the pathogen-
esis of systemic disorders has been recognized since antiquity, a
firm scientific basis for a role for the gut microbiome in liver dis-
ease did not emerge until the middle of the last century with the
recognition of the relationship between hepatic coma and the
absorption of nitrogenous substances from the intestine [1]. This
was followed by the description of abundant coliforms in the
small intestine of cirrhotics [2] and the role of bacteria was
clinched by trials demonstrating that antibiotics led to clinical
improvement in hepatic encephalopathy (HE) [3]. Subsequently,
these same gut-derived bacteria were implicated in another com-
plication of chronic liver disease and portal hypertension, sponta-
neous bacterial peritonitis. Most recently, more credence has
been given to a suggestion that has lingered in the background
for decades, namely, that the gut microbiota might play a role
in the pathogenesis or progression of certain liver diseases,
including alcoholic liver disease [4], non-alcoholic fatty liver dis-
ease (NAFLD) and non-alcoholic steato-hepatitis (NASH) [5], total
parenteral nutrition (TPN)/intestinal failure-related liver disease
(IFALD) [6], and primary sclerosing cholangitis (PSC) [7], either
through the direct effects of bacteria or their products, via inflam-
matory mediators such as tumor necrosis factor a (TNF), whose
release had been triggered by constituents of the microbiota, or,
as in the case of primary sclerosing cholangitis (PSC), through
cross-reactivity between microbial antigens and human tissue
components (e.g., atypical anti-nuclear cytoplasmic antibodies
(p-ANCA), in PSC, recognize both tubulin beta isoform 5 in human
neutrophils, and the bacterial cell division protein FtsZ) [8].Journal of Hepatology 20
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the development and maintenance of the hyperdynamic circula-
tion that is a feature of portal hypertension [9], in impairing liver
function and contributing to haemostatic failure [10]. It is in
these contexts that modulation of the microbiota has emerged
as a potential therapeutic strategy in the management of liver
disease.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.The microbiota in the pathogenesis of liver disease and its
complications
The human intestinal microbiota consists of trillions of microor-
ganisms including 150–200 prevalent and 1000 less common
bacterial species, harbouring over 100-fold more genes than those
present in the human genome [11–13]. This microbiota consists
predominantly of bacteria, but also contains archaea, protozoa,
and viruses; all have co-evolved with the human host. The micro-
biota performs vital functions essential to health maintenance,
including food processing, digestion of complex indigestible poly-
saccharides and synthesis of vitamins [14,15]. Furthermore, it
secretes a range of bioactive metabolites with diverse functions,
ranging from inhibition of pathogens, metabolism of toxic com-
pounds to modulation of host metabolism [15]. A perturbed mic-
robiota has been implicated in an ever-increasing list of disorders
in humans, from necrotizing enterocolitis (NEC) in infants, to
obesity, diabetes, metabolic syndrome, irritable bowel syndrome
(IBS), and inflammatory bowel disease (IBD) in adults [16–21].
However, little is known about the physiological impact the mic-
robiota has on host health, an area which has recently been
described as ‘‘one of the hottest areas in medicine’’ [22].
Table 1 lists a number of mechanisms that might underpin the
role of the microbiota in the pathogenesis of liver disease and/or
its complications.
Small intestinal bacterial overgrowth (SIBO)
Among the various potential contributions of the microbiota to
liver disease, small intestinal bacterial overgrowth (SIBO) has
been one of the most extensively studied. Indeed, an altered gut13 vol. 58 j 1020–1027
Key Points
• The microbiota performs vital functions including
food processing, digestion of complex indigestible
polysaccharides and synthesis of vitamins
• The advent of molecular techniques now permits
the complete delineation of the constituents of the
microbiota in health and disease 
• Changes in the microbiota have been identified in
relation to a number of liver diseases and implicated in
the pathophysiology of NAFLD/NASH, alcoholic liver
disease, and IFALD, in particular
• Small intestinal bacterial overgrowth has been
associated, in cirrhosis, with bacteraemia, SBP, and
HE
• Modulation of the microbiota, by antibiotics, is 
an established strategy in the management and
prevention of a number of complications of chronic liver
disease
• While probiotics hold promise in the management of
liver disease, and their potential is supported by a
considerable volume of laboratory work, high-quality
clinical evidence is scanty
JOURNAL OF HEPATOLOGYmicrobiota was first noted by Hoefert in chronic liver disease over
80 years ago [23]; since then SIBO has been documented to be
common in liver disease, to correlate with its severity and to be
linked tominimal and overt encephalopathy and an increased risk
for SBP through translocation across the gut wall [24–28]. More-
over, factors predisposing to SIBO such as altered small bowel
motility, increased intestinal permeability, and delayed gut
transit have been reported in patients with liver cirrhosis [29].
Alterations in gastrointestinal motility in cirrhosis have been
variably ascribed to the effects of autonomic dysfunction, altered
levels of circulating neuropeptides and the effects of inflamma-
tory mediators on gut muscle and nerve [9,29]. With regard to
intestinal permeability, changes in intestinal tight junctional pro-
teins have been described in cirrhosis and, though the preciseTable 1. The microbiota in the pathogenesis of liver disease and its complications. P
Microbial factor Examples of mediator(s
Small intestinal bacterial overgrowth Multiple
Alterations in the composition of the microbiota Multiple
Translocation of bacteria or bacterial 
components 
Lipopolysaccharide, en
Direct effects of products of gut bacterial 
metabolism 
Acetaldehyde, 
TMA, TMAO
Immune response to a normal or abnormal 
microbiota 
Cross-reactivity betwee
tissue components
Effects of cytokines released in response to 
the microbiota 
TNFα
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; IFALD, inte
trimethylamine; TMAO, trimethylamine oxide; PSC, primary sclerosing cholangitis; TNF
Journal of Hepatology 2013pathophysiology of barrier dysfunction is unclear, roles formetab-
olites of alcohol and/or pro-inflammatory cytokines have been
postulated [4,5,7,30,31]. Impaired antimicrobial defence mecha-
nisms may further contribute to the development of bacterial
translocation in portal hypertension and cirrhosis [30]. Taken
together, these observations have led to the development of a
schema which links intestinal motility, stasis, increased intestinal
permeability and translocation of bacteria and endotoxin to the
development of many of the complications of liver disease, as well
as in the progression of liver disease, per se (Fig. 1).
A more fundamental role for SIBO has been proposed in both
alcoholic liver disease (through the generation of acetaldehyde)
[31] and NAFLD (by promoting both steatosis and inflammation)
[5]. The potential of microbes of enteric origin to induce a pro-
gressive and even fatal steato-hepatitis had been recognized
some years ago in relation to the liver injury that complicated
jejuno-ileal bypass operations for morbid obesity; indeed, that
procedure has provided a valuable experimental model for
exploring the impact of the microbiota in liver disease.
Quantitative or qualitative changes in the microbiota
The advent of molecular techniques based on sequence diver-
gences of the small subunit ribosomal ribonucleic acid (16S
rRNA) of bacteria [32] now permits the complete delineation of
the constituents of the microbiota in health, thereby, revealing
the composition of the human gut microbiota from early infancy
[33] through to old age [34,35]. Following birth, the human intes-
tine is rapidly colonized and factors known to influence coloniza-
tion include gestational age, mode of delivery (vaginal birth vs.
assisted delivery), diet (breast milk vs. formula), level of sanita-
tion, and exposure to antibiotics [15,36]. The intestinal microbi-
ota of newborn infants is characterized by low diversity and a
relative dominance of the phyla Proteobacteria and Actinobacteria;
thereafter, the microbiota becomes more diverse with the emer-
gence of the dominance of Firmicutes and Bacteroidetes, which
characterises the adult microbiota [12,14,37]. By the end of the
first year of life, infants possess a microbial profile distinct for
each infant; by 2.5 years of age, the microbiota fully resembles
that of an adult in terms of composition [33,38]. More recently,
three different ‘enterotypes’ have been described in the adult
human microbiome [39] These distinct ‘enterotypes’ are domi-
nated by Prevotella, Ruminococcus, and Bacteroides, respectively,ossible factors.
) Clinical implications
NAFLD/NASH
IFALD
Obesity
dotoxin SBP
Other infectious complications of 
liver disease
Portal hypertension
Alcoholic liver disease
NAFLD/NASH
n bacterial antigens and host PSC
NAFLD/NASH
Portal hypertension
stinal failure-associated liver disease; SBP, spontaneous bacterial peritonitis; TMA,
a, tumor necrosis factor alpha.
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Intestine
Impaired motility, 
stasis
Increased translocation
of bacteria/endotoxin/LPS
to portal circulation
Enhanced release of 
pro-inflammatory cytokines
Altered composition
of the gut microbiota
Increased
epithelial permeability SIBO
SIBO
Portal-systemic
shunting
Fig. 1. A schema to explain potential roles of the small intestinal bacterial
overgrowth (SIBO) in liver disease and its complications. Impaired motility
promotes stasis; quantitative and qualitative changes in the small intestinal
microbiota ensue leading to the development of small intestinal bacterial
overgrowth (SIBO). Alterations in the integrity of the intestinal barrier result in
enhanced permeability and facilitate the translocation of bacteria or their
products into the portal circulation. Changes in the enteric microbiota also lead
to the enhanced release of pro-inflammatory cytokines which enhance translo-
cation and exert a variety of effects on liver structure and function. If portal-
systemic shunting is present, access for the products of translocation and
cytokines to the systemic circulation is enhanced.
Reviewand their appearance appears to be independent of sex, age,
nationality and body mass index (BMI). Once the microbiota
has reached maturity, it is thought to remain stable until old
age when changes are seen, possibly related to alterations in
digestive physiology and diet [13,40,41]. Indeed, Claesson et al.
were able to identify clear correlations, in the elderly, not only
between the composition of the gut microbiota and diet, but also
with health status [35].
These molecular approaches have, to some extent, been direc-
ted at the investigation of the microbiota in liver disease. Chen
et al., for example, studied 36 patients with cirrhosis and 24
healthy controls using 454 pyrosequencing of the 16S ribosomal1022 Journal of Hepatology 2013RNA variable region 3 (V3) followed by real-time quantitative
polymerase chain reaction (qPCR) and found that, in cirrhosis,
Bacteroidetes were reduced, Proteobacteria and Fusobacteria
increased, Enterobacteriaceae, Veillonellaceae, Streptococcaceae
increased, and Lachnospiraceae reduced [42]. Some of these
changes correlated with clinical parameters such as the Child-
Turcotte-Pugh score. Several of these findings have been con-
firmed by Bajaj et al. who went on to show that Veillonellaceae
were more abundant among cirrhotics with hepatic encephalop-
athy (HE) than those without [43]. As an extension of the evolv-
ing concept of the microbiota–gut–brain-axis, which includes the
suggestion that the microbiota can influence cognition and
behaviour, these authors also described an association between
certain bacterial families, cognition and inflammation in HE.
The finding of an increased abundance of members of the family
Enterobacteriaceae in cirrhosis by these and other authors [44] is
of interest given that this family includes such important Gram-
negative pathogens as Salmonella, Shigella, Yersinia pestis, Klebsi-
ella and, especially, Escherichia coli, a common isolate in SBP
and bacteremia in chronic liver disease. Others have documented,
not only a decrease in total bifidobacterial counts, but also fur-
ther variations in specific Bifidobacterium species (e.g., Bifidobac-
terium dentium increased; Bifidobacterium longum decreased) in
chronic liver disease [45].Interactions with diet and nutrients
Several mechanisms have been identified relevant to the
involvement of the microbiota in the pathogenesis of NAFLD/
NASH. In particular, a role for the microbiota and its interac-
tion with diet in the pathogenesis of obesity per se has been
extensively investigated [46,47], and pertinent findings include
the ability of Gram-negative anaerobes, such as Bacteriodes the-
taiotamicron, to cleave most glycosidic linkages, degrade plant
polysaccharides and, thereby, supply the host with 10–15% of
its calorific requirement [11,17,46,47]. The microbiota of obese
individuals, as well as the caecal microbiota of ob/ob mice, are
more efficient at the extraction of energy from the diet and in
the production of short chain fatty acids (SCFAs) [11,48]. Fur-
thermore, the microbiota has been shown to stimulate hepatic
triglyceride production through suppression of the lipoprotein
lipase (LPL) inhibitor, fasting-induced adipose factor (Fiaf; also
known as angiopoietin-like 4), thereby leading to continued
expression of LPL, a key regulator of fatty acid release from tri-
glycerides in the liver [49]. The gut microbiota can also modu-
late systemic lipid metabolism through modification of bile
acid metabolic patterns, impacting directly on the emulsifica-
tion and absorption properties of bile acids and thus, indirectly,
on the storage of fatty acids in the liver. The microbiota has
also been implicated in the development of insulin resistance
[49], a fundamental abnormality in the metabolic syndrome,
by affecting energy balance, glucose metabolism, and the
low-grade inflammatory state that has been associated with
obesity and related metabolic disorders. Its role in choline
metabolism [50–52], as well as in activation of pro-inflamma-
tory cytokines (e.g., TNFa), appears relevant to the develop-
ment of NAFLD and progression to NASH. Most recently,
studies in experimental models have shown that defective/defi-
cient inflammasome sensing and related dysbiosis result in an
abnormal accumulation of bacterial products in the portal cir-
culation and promote progression of NAFLD/NASH [53].vol. 58 j 1020–1027
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Interactions with alcohol
Alcohol-related liver injury may also involve the active participa-
tion of the microbiota through a number of mechanisms [31].
Firstly, alcohol promotes the growth of Gram-negative bacteria
in the gut with the consequent production of endotoxin. Sec-
ondly, Gram-negative bacteria metabolize alcohol to acetalde-
hyde which, in turn, increases intestinal permeability. Other
effects of alcohol conspire to increase permeability, promote
transfer of endotoxin across the intestinal epithelium and impair
the host immune response [31]. Protein adducts formed from
metabolites of alcohol have also been shown to combine with
LPS to induce liver injury [54].Therapeutic impact of modulating the microbiota
Antibiotics
Infectious complications. Reflecting the involvement of the micro-
biota in the genesis of the infectious complications of liver
disease [55], the fundamental role of antibiotic therapy directed
at Gram-negative enteric bacteria, in the management and pre-
vention of infectious complications of liver disease and portal
hypertension and chronic liver disease, such as SBP and bacter-
aemia, is well established [56]. Indeed, antibiotics have also been
advocated to both prevent infectious complications and reduce
re-bleeding rates among patients with variceal haemorrhage
[10,56,57]. Based on the aforementioned role of endotoxemia
resulting from bacterial translocation in the pathogenesis of the
hyperdynamic circulation that characterizes portal hypertension
(through the induction of nitric oxide [NO] synthase), selective
intestinal decontamination has also been proposed as a strategy
in the management of the circulatory complications of cirrhosis
[58].Hepatic encephalopathy
The recent studies, indicating the efficacy of the poorly
absorbed antibiotic with activity against enteric organisms, rif-
aximin, in overt [59] and sub-clinical [60] HE, have bolstered
the importance of the role of these organisms in the pathogen-
esis of this common complication of liver disease; the precise
nature of the changes in the composition and/or metabolic
activity of the microbiota that generate these benefits remains
to be determined.Intestinal failure-associated liver disease (IFALD)
The term intestinal failure-associated liver disease has replaced
that of total parenteral nutrition (TPN)-associated liver disease
to describe alterations in liver morphology and function that
occur among subjects with intestinal failure who may or may
not also be on TPN. The etiology of intestinal failure-associated
liver disease (IFALD) is multifactorial, with primary contributors
including prematurity (in infants), sepsis, nutritional deficiencies
or hepatotoxic effects of TPN infusates, and lack of enterally stim-
ulated bile flow [61]. Though SIBOmay be an important feature in
intestinal failure of various aetiologies and has been implicated in
the pathogenesis of IFALD, there is currently insufficient evidence
to support the use of antibiotics, such as metronidazole, in the
prevention of IFALD [62].Journal of Hepatology 2013Probiotics and prebiotics
Experimental
NAFLD: In a pioneering study in the ob/ob mouse (an animal
model of NAFLD), Li et al. compared the probiotic cocktail
VSL#3 to an anti-TNFa antibody. Though, in comparison to the
anti-TNFa antibody, VSL#3 had less effect on steatosis, its impact
on inflammation and liver injury was similar, yet did not appear
to be exerted through a reduction in hepatic expression of TNFa
[63]. In a model that is more relevant to humans, diet-induced
obesity, Ma et al. showed that the same probiotic preparation
could prevent the development of steatosis through a natural
killer T-cell (NKT)-dependent mechanism [64]; in contrast, other
workers found that VSL#3, while attenuating fibrosis, had no
effect on either steatosis or steatohepatitis in NASH induced by
a methionine-choline-deficient diet [65]. Based on their studies,
Xu et al. concluded that B. longum was more effective than Lacto-
bacillus acidophilus in NAFLD and that these beneficial effects
were related to a modification of the gut microbiota [66]. Our
own studies have shown that the modulation of the enteric mic-
robiota can influence the fatty acid composition of host tissues,
including the liver, adipose tissue, and brain [67,68]. Thus, we
observed a significant elevation in c9, t11 conjugated linoleic acid
(CLA) in the livers of mice and pigs, after feeding with linoleic
acid in combination with the probiotic organism Bifidobacterium
breve NCIMB 702258. CLA is a microbial metabolite that has been
associated with the alleviation of NAFLD [69]. Indeed, it is note-
worthy that the VSL#3 probiotic cocktail has been shown to pro-
duce CLA in vitro, and the c9, t11 CLA isomer, in particular [70]
Prebiotic preparations have also been shown to ameliorate liver
inflammation in obese mice through a glucagon-like peptide-2
(GLP-2)-dependent effect on the gut barrier [71] and hold prom-
ise for the management of NAFLD and related disorders [72].
Alcoholic liver disease: In an animal model of alcoholic liver
disease, Forsyth et al. found that Lactobacillus rhamnosus GG
(LGG) could reduce liver fat content, necro-inflammatory score
and myleoperoxidase expression. Interestingly, these beneficial
effects correlated with a reduction in, or normalization of, intes-
tinal permeability [73]. Indeed, the concept that a significant
component of the beneficial effect of probiotics in alcohol-related
liver injury is exerted at the level of the intestinal barrier is sup-
ported by other studies [74], as well as by a considerable litera-
ture attesting to important effects of probiotics on gut tight
junctional and transcellular permeability in diverse disease mod-
els. Indeed, Wang et al. have provided a molecular basis for the
action of the probiotic L. rhamnosus GG, one of the most widely
studied organisms in this context, by demonstrating that the res-
toration of barrier function, in alcohol-induced liver injury, was
mediated through the recovery of hypoxia-inducible factor
(HIF) and trefoil factor in gut epithelial cells [75].
Complications of liver disease: A variety of probiotic prepara-
tions have been studied in relation to the various complications
of liver disease. While Lactobacillus-fermented milk supplements
failed to reduce bacterial translocation in an experimental model
of prehepatic portal hypertension [76], in contrast, in a model of
acute liver injury, Adawi et al. found that rectal administration of
a number of Lactobacillus species, with or without arginine sup-
plementation, led to a reduction in bacterial translocation. In this
same model, Lactobacillus plantarum alone abrogated the severity
of the liver injury [77]. In an animal model of minimal HE, Jia and
Zhang showed that a probiotic cocktail was as effective as lactu-
lose in reducing HE and blood ammonia levels as well as decreas-
ing endotoxaemia, liver injury and inflammation [78].vol. 58 j 1020–1027 1023
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Effects on acute liver injury and chronic liver disease: Probiotics
have been shown to reduce the impact of a variety of forms of
acute liver injury [79–83], as well as the severity of more chronic
forms of liver disease, such as that related to total parenteral
nutrition (TPN) [84].
Clinical
Given all that has been reviewed above, it should come as no sur-
prise that here is an ever-increasing interest in the potential ther-
apeutic value of probiotics in a variety of contexts in relation to
the liver and its diseases [61,85,86]. These include: HE, transloca-
tion and infectious complications, NAFLD/NASH and the prophy-
laxis of infections after liver transplantation [86]. In attempting
to assess the relevant literature, the reviewer is confronted, not
only by the issues that bedevil the interpretation of animal stud-
ies (varying probiotic strains and preparations, different animal
models and outcomes), but also by limitations in study size and
design, as well as variations in probiotic dose, formulation, route
and duration of therapy. There is also limited data on the micro-
biological impact of probiotics on the abnormal microbiota that
has been described in cirrhosis and other liver diseases [87].
While probiotics are generally assumed to be safe, there have
been reservations regarding their use in immunosuppressed
individuals; whether these preparations offer a greater risk of
initiating septic complications among individuals with liver
disease, given the presence of both portal-systemic shunting
and impaired immune function (be it related to underlying
disease or iatrogenic), is unclear and safety assessments have
been limited [86].
NAFLD/NASH: A Cochrane Collaboration Systematic Review
published in 2007, while failing to identify any randomized clin-
ical trials, concluded that preliminary data from two pilot non-
randomised studies suggested that probiotics may be well toler-
ated, improve conventional liver function tests and decrease
markers of lipid peroxidation in NAFLD/NASH [88]. Their review
included one study employing L. Bulgaricus, which produced a
reduction in transaminases [89], and another with L. rhamnosus
GG, which resulted in lower levels of alanine transaminase [90].
Alcoholic liver disease: Kirpich et al. randomized 66 Russian
males with alcoholic psychosis to 5 days of therapy with a com-
bination of Bifidobacterium bifidum and L. plantarum or standard
therapy. At baseline, alcoholics had fewer bifidobacteria, lactoba-
cilli and enterococci; however, after 5 days of probiotic therapy,
bifidobacteria, and lactobacilli increased and, when checked
7 days after the initiation of probiotic therapy, alanine transami-
nase levels had declined significantly in the probiotic but not in
the control group [91].
Complications of liver disease: Despite the presence, in the lit-
erature, of several individual trials attesting to the benefits of var-
ious probiotic preparations in HE and minimal/subclinical HE
[92–95], a recent Cochrane Systematic Review concluded that,
while probiotics appeared to exert a significant effect on blood
ammonia levels, problems with trial interpretation (related, in
turn, to shortcomings in study design) did not allow them to con-
clude that probiotics were effective against clinically meaningful
end points [96]. It should be noted, however, that a separate sys-
tematic review that focused exclusively on minimal HE con-
cluded that prebiotics, probiotics, and synbiotics were effective
for this indication, but that lactulose (itself a prebiotic) was supe-
rior to both probiotics and synbiotics [97]. Similar issues limit
one’s ability to draw conclusions and generate recommendations
regarding the role of probiotics in preventing infectious compli-1024 Journal of Hepatology 2013cations of liver disease. While reported effects of probiotics on
modulating the microbiota [86,98], reducing levels of endotoxe-
mia [98], normalizing impaired neutrophil function [99] and
reducing levels of pro-inflammatory cytokines [100] could well
translate into clinical benefit, this has yet to be demonstrated.
The efficacy of lactulose, a prebiotic, and antibiotics, such as neo-
mycin, paromomycin, and rifaximin, in HE, has been well docu-
mented. A recent meta-analysis suggested that the efficacy of
rifaximin was similar to that of lactulose and older antibiotic
regimes but associated with less adverse events [101]. There have
been limited studies of probiotics in other complications; the
probiotic cocktail VSL#3 had no effect on portal pressure in either
compensated or very early decompensated cirrhosis [102].
Effects on acute liver injury and chronic liver disease: Data on
the impact of probiotics on the evolution or natural history of
liver disease, per se, is very limited. Though uncontrolled studies
suggest that probiotics may reduce SIBO in IFALD, there is, as yet,
no evidence that their administration can prevent the develop-
ment or progression of this form of liver disease [61]. Similarly,
small studies in compensated cirrhosis [103] and PSC [104]
showed no impact from the relatively short-term (3–6 months)
administration of probiotic on common laboratory parameters.
While probiotic supplementation has been shown to reduce a
biomarker of risk for hepatocellular cancer [105], the actual clin-
ical impact of this approach is unknown.Conclusions and future studies
A central role for the microbiota in the precipitation of infectious
and non-infectious complications of liver disease has been estab-
lished and evidence for a more fundamental role in the aetiology
of certain liver diseases, such as NAFLD and NASH, continues to
accumulate. However, the description of the microbiota and its
metabolic [106] and immunological [107] functions in various
forms and stages of liver disease is still far from complete, but
should be nigh given the widespread availability of high-
throughput sequencing and metabolomic technologies. While
high quality clinical evidence supports the use of antibiotic ther-
apy, presumably as a modulator of the microbiota, in the man-
agement of HE, SBP, and other infectious complications, how
these interventions impact on the microbiota and microbiota-
host interactions has not been clearly defined. While probiotics
hold promise in the management of liver disease and their poten-
tial is supported by a considerable volume of laboratory work
[108], high-quality clinical evidence is scanty and its paucity,
together with all of the quality control, strain selection and dose
optimization issues that have been an unfortunate feature of this
field, precludes, for the moment, recommendations on the use of
probiotics, in general, and specific strains, in particular, in clinical
practice. However, there is a sufficiently strong rationale for the
use of strategies that involve the modulation of the microbiota
in the management of liver diseases, such as NAFLD [109–111],
and their complications to suggest that these approaches are
deserving of further exploration.Conflict of interest
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